@Bioglovesadam oh my
Just seeing all these posts
Triggered an understatement
Show me on this doll where Sushi touched you
Will block you after tomorrow
I’ll have fun w you 4 24 hrs and move on
All this for a “100 share spec play”?
Poor people. Adorable, right?
Cheers
German Chancellor Merz: Tomorrow is June 6th, D-Day, when the Americans once ended a war in Europe
Trump: “That was not a pleasant day for you."
Merz: “This was the liberation of my country from Nazi dictatorship” (2025)
Immix Biopharma will participate in the Jefferies Global Healthcare Conference, June 2–4, 2026, in New York, NY.
Our management team will be available for one-on-one institutional investor meetings throughout the conference. To request a meeting, please contact your Jefferies representative.
Press Release: https://t.co/Rd4kKxbLHo
#IMMX #ALAmyloidosis #Biopharma #JefferiesConference $IMMX
As we advance toward BLA submission for investigational NXC-201, we are proud to welcome Richard Graydon, MD, PhD, as Chief Medical Officer of Immix Biopharma.
Dr. Graydon is a board-certified hematologist-oncologist with over 20 years of experience in clinical development, most recently at Merck & Co. and Johnson & Johnson. He led biologics license applications and new drug applications for 7 FDA-approved drugs, including KEYTRUDA, DARZALEX, CARVYKTI, and IMBRUVICA.
His deep BLA experience and rare disease expertise make him uniquely positioned to lead NXC-201 through the final stages of development as we work toward what could be the first FDA-approved treatment for relapsed/refractory AL Amyloidosis.
Read the full press release: https://t.co/9sQD672UZX
#IMMX #ALAmyloidosis #RareDisease #Biopharma #Hematology $IMMX